全球新冠累计确诊已超过1585 万人，每日新增确诊持续增加已超过28 万人，累计死亡病例接近64 万人。主要人口大国里中日韩+欧洲已经基本得到控制，美国、巴西、印度、俄罗斯、南非疫情严重，除俄罗斯以外每日新增确诊病例均处于爬坡阶段。中国新冠疫情控制良好，但仍然存在局部爆发的风险，如东北、北京、香港、新疆都出现过局部爆发。全球期盼新冠疫苗上市，从而彻底控制疫情。

近日，国务院办公厅印发《深化医药卫生体制改革2020 年下半年重点工作任务》，在今年新冠疫情突发背景下，下半年工作任务着重强调要统筹推进深化医改与新冠肺炎疫情防治相关工作，把预防为主摆在更加突出位置，继续着力推动把以治病为中心转变为以人民健康为中心，深化医疗、医保、医药联动改革，继续着力解决看病难、看病贵问题，为打赢疫情防控的人民战争、总体战、阻击战，保障人民生命安全和身体健康提供有力支撑。

介绍了DNA/RNA 在机体作用机制，及脂质体辅助下作为疫苗在体内诱导免疫反应的发现过程，并比较几类疫苗优劣势。之后分别对DNA 疫苗和RNA 疫苗的研发、制备和工业生产情况进行细致阐述，着重分析两类技术的优缺点对生产的影响。最后列举了重要DNA 疫苗研发进展及对COVID-19 研发的借鉴作用，概括当前COVID-19 疫苗产品研发进展，并对相关产品临床结果进行点评。

医药生物板块上周累计上涨0.41%，全部A 股（加权平均）下跌0.70%，医药生物板块跑赢大盘1.11%，涨幅在申万28 个一级子行业中排名第11 位。七个子板块中生物制品涨幅居首，累计涨幅为3.44%，化学制剂、医疗器械板块出现小幅回调，分别下跌1.21%和0.96%。从估值水平来看，医药生物板块市盈率（TTM，整体法）为55.66 倍（截止2020 年7 月24 日），全部A 股市盈率为17.78 倍，医药生物板块相对于全部A 股的估值溢价率为212.99%。本周申万医药生物板块共有154 家上涨，185 家下跌，其中威尔药业、海辰药业及贝瑞基因涨幅居前，而赛诺医疗、通化东宝、硕世生物的跌幅最多。

医药指数基本持平。从子板块来看，医疗服务上涨0.63%，化学制药下跌0.26%，医疗器械下跌0.90%，生物制品上涨4.41%，中药上涨0.30%，医药商业下跌0.82%。本周前四天医药指数在上周调整基础上稳步回升，周五受大盘系统调整影响，大幅下调5.85%，基本回吐全周涨幅。

自2月中国疫情出现拐点后，中国（不含港澳台）每日新增疫情数量不断下降，整体上看我国疫情得到了有效控制。局部地区如北京、新疆、大连等偶见反弹，可以预见，随着海外疫情的不断恶化，中国的境外输入风险将会持续加大，输入病例也会引发疫情的局部传播扩散，虽然整体上疫情得到有效控制，防控挑战及压力依然较大。截至2020年7月23日，海外新冠肺炎确诊累计约1556万人，创历史新高，累计死亡病例已经达到63万人。全球疫情的持续发展突出了疫苗研发的迫切性，从预防角度看，疫苗是阻断疫情传播扩散的根本措施。

TO C为主的互联网医疗平台以挂号、咨询、问诊、医药等多样化服务为商业化途径，意图打造基 于医、药、健康为一体的业务闭环，并基于其中的1-2项为流量入口，打造核心业务。

Infectious disease rapid diagnostic testing is primarily adopted for the diagnosis of various infectious diseases in a restricted clinical environment. These testing primarily relies on the detection of the target analyte, offering clinical insights in a stipulated time frame. Such testing is becoming an integral component of the healthcare system across the globe. The adoption of these tests in the healthcare system has aided clinicians in navigating through tough times during the outbreak of highly contagious infections, such as Ebola virus disease (EVD), SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), and COVID-19.

A laparoscope comprises a long, thin tube with high intensity light along with high resolution camera in front. The camera transmits images to monitor as it travels through the abdomen. Laparoscopy is used for diagnosis as well as treatment of endometriosis, ectopic pregnancy, pelvic inflammatory disease (PID), cysts, and fibroids. The report includes the revenue generated from all devices used for laparoscopic procedures, and the revenue generated by laparoscope device manufacturers. Revenue generated by clinics or hospital services provided to patients through use of laparoscope devices is excluded from the market, as this revenue, known as service cost, is earned by respective hospitals and clinics among end users.

The global continuous glucose monitoring (CGM) systems market is segmented based on component, end user, demographics, and geography. The report includes the revenue generated from the sale of various continuous glucose monitoring systems, but excludes the revenue generated by dealers, traders, or brokers involved in the supply of the systems.Diabetes, a chronic lifestyle disease, is classified into type 1 and type 2 diabetes. In type 1 diabetes, the pancreas is unable to produce sufficient or requisite amount of insulin hormone that is required for metabolizing glucose. In type 2 diabetes, the pancreas produces insulin, but the cells lack the ability to respond and/or do not uptake the insulin available in the blood stream. The symptoms of diabetes include: